Lundbeck Sweden

GPTKB entity

Statements (63)
Predicate Object
gptkbp:instanceOf gptkb:Company
gptkbp:acquisition gptkb:Ovation_Pharmaceuticals
gptkb:H._Lundbeck_A/S
gptkbp:awards various industry recognitions
gptkbp:CEO gptkb:Deborah_Dunsire
gptkbp:clinicalTrials ongoing
collaborative studies
Phase II trials ongoing
Phase III trials ongoing
focus on innovative treatments
gptkbp:collaborations academic institutions
gptkbp:communityInvolvement mental health initiatives
gptkbp:culturalHeritage commitment to workplace diversity
gptkbp:employees approximately 5,000
gptkbp:focusesOn neurology
gptkbp:founded 1915
gptkbp:headquarters Copenhagen,_Denmark
https://www.w3.org/2000/01/rdf-schema#label Lundbeck Sweden
gptkbp:investmentFocus R&D investments
gptkbp:localEconomy improving mental health treatment
gptkbp:manufacturer gptkb:Copenhagen
gptkbp:market growing_in_Asia
strong_in_Europe
expanding_in_North_America
gptkbp:operatesIn global market
gptkbp:partnerships with healthcare providers
various biotech companies
with patient advocacy groups
gptkbp:patentCitation numerous in CNS field
gptkbp:products antidepressants
antipsychotics
gptkbp:research support for mental health research
gptkbp:research_areas gptkb:schizophrenia
Alzheimer's disease
Parkinson's disease
depression
addiction
anxiety disorders
bipolar disorder
pain management
epilepsy
mood disorders
gptkbp:researchFocus patient-centered care
neuroinflammation
digital health solutions
neurodegeneration
psychopharmacology
clinical pharmacology
real-world evidence studies
CNS disorders
biomarkers in CNS
genetic research in psychiatry
health economics in mental health
novel drug delivery systems
gptkbp:revenue approximately 2 billion EUR
gptkbp:socialResponsibility community health programs
healthcare_access_initiatives
gptkbp:stockExchange gptkb:Copenhagen_Stock_Exchange
gptkbp:stockSymbol LUN
gptkbp:subsidiary gptkb:Lundbeck_LLC
gptkb:Lundbeck_Ltd.
gptkbp:sustainability environmental responsibility
gptkbp:website www.lundbeck.com